antibiotics

The Geneva-based Global Antibiotic Research and Development Partnership (GARDP) announced Tuesday that it has signed a memorandum of understanding (MOU) with the Clinton Health Access Initiative (CHAI) and Shionogi to accelerate LMIC access to the Osaka-based drugmaker’s antibiotic cefiderocol (Fetroja).

The collaboration will help introduce the drug—indicated for bacterial infections in patients with limited treatment options—into health systems and provide clinical guidance to…

The Access to Medicine (AtM) Foundation released a new report last week highlighting some biotechs that are finding novel ways to get badly needed antibiotics to patients in low- and middle-income countries despite notoriously difficult market conditions.

Drawing on “new data and discussions with stakeholders,” the report said that small- and medium-sized companies (SMEs) now account for 75% of all late-stage antimicrobials in the R&D pipeline, with many large companies having…

CARB-X announced Tuesday that it will give Swiss biopharma BioVersys up to $4.3 million (plus up to $11 million in milestones) to develop new antibiotics to treat life-threatening infections caused by multidrug-resistant “ESKAPE” pathogens, including E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species.

BioVersys’ novel class of pyrrolocytosine small molecules have exhibited “robust coverage” of all relevant Gram-negative pathogens as well as other…

Boston University’s CARB-X consortium announced two new investments this week.

On Tuesday, the nonprofit said it will give Massachusetts-based Summit Therapeutics up to $4.1 million (plus up to $3.7 million in milestones) to develop its first-in-class SMT-738 antibiotic candidate for treating multidrug-resistant infections—specifically carbapenem-resistant Enterobacteriaceae (CRE) infections caused by pathogens including E. coli and K. pneumoniae. The funds will help advance the…

Boston University-led CARB-X announced Tuesday that it will give British diagnostics company GenomeKey $3 million (plus up to $6.5 million in milestones) to develop a four-hour test for sepsis. The diagnostic uses machine learning to identify bacterial species and test for antibiotic sensitivity, allowing clinicians to prescribe targeted drugs quickly and “reduce unnecessary antibiotic consumption,” the press release said.

Meanwhile, Massachusetts-based biotech X-Biotix announced…

Funders made new investments in antibiotics, diagnostics and bacteriophage drugs in recent days.

Boston University-led CARB-X announced two new awards. On Monday, the nonprofit said it would give Britain’s Phico Therapeutics up to $5.3 million (plus up to $12.9 million in milestones) to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia caused by P. aeruginosa. On Tuesday, CARB-X announced an award of up to $3.9 million (plus up to $7.7…

CARB-X announced on Tuesday up to $2.2 million in funding for the University of Queensland’s octapeptin potentiator research program, which aims to develop a new drug that disables the protective cell membrane of drug-resistant Gram-negative bacteria.

Low- and middle-income countries could use engineered octapeptin peptides to “breathe new life” into old antibiotics, according to the press release.

Mentions:

Novartis’ generics subsidiary Sandoz announced last week an agreement to acquire GSK’s cephalosporin antibiotics business for $350 million upfront, plus up to $150 million in milestones.

The deal includes rights in more than 100 markets to three established brands with combined 2020 sales of $140 million, according to Novartis.

Novartis also invested in antibiotic expansion last year.

CARB-X announced two new investments in the first days of February.

The Boston University-led nonprofit will award up to $12.2 million to France’s Mutabilis to develop a new intravenous drug to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.

CARB-X will also invest up to $17.2 million in California-based diagnostics specialist Avails Medical to fund the company’s high-speed electronic antibiotic-susceptibility testing device for blood infections…

PNAS published a preclinical study Monday of commonly used tetracycline-based antibiotics, including U.S. FDA-approved methacycline, showing that these drugs may slow infection and reduce neurological problems caused by the Zika virus, according to an NIH press release.

The joint U.S. National Institutes of Health and Georgetown University preclinical study also identified J&J’s failed anti-Alzheimer’s drug, JNJ-404, and Merck’s investigational anti-inflammatory medicine, MK-591,…

Mentions: